This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
While it has always been presumed that neoplasia is a consequence of somatic cell mutations, only in the last few years has the
magnitude and diversity of these mutations been elucidated by modern DNA sequencing technology. Immunotherapy
is the premier biological approach to targeted therapy. Target therapies require targets. In this case the targets are tumor
specific or associated antigens, the proteins expressed from these somatic cell mutations. While the immunotherapeutic
approach to eliminating cancer was launched with the assumption that cancer cells were homogeneous, the recent genomic
understanding of tumor cells indicates that there is both inter- and intra-tumoral heterogeneity. This presentation will discuss
the consequences of this new knowledge of tumor cell biology to the immunotherapeutic approach to treating cancer. What
is more, this presentation will discuss the translational development of an active specific immunotherapeutic approach from
preclinical to beneficial clinical benefit.
Michael G Hanna, Jr. received his PhD in Experimental Pathology and Immunology from the University of Tennessee in 1964. He also served as a consultant
with NASA for the lunar receiving laboratory during Apollo 11 and 12, for which his expertise in immunology was used in the testing of the lunar core powder for
immunogenic or pathogenic materials. He served during1975-83 as Director of the National Cancer Institute, Frederick Cancer Research Center (MD, USA).
Subsequently, he founded PerImmune Inc., in which he served as President and Chief Executive Officer. In 2007, he founded Vaccinogen Inc., where he served as
Chairman and CEO. Currently, he is Chairman Emeritus. He served as Chairman of the Department of Commerce Biotechnology Advisory Committee (1984-9) and
also participated in the Department of Defense Technical Working Group for Biotechnology (1988-9). His research resulted in over 225 publications in international
peer-reviewed journals and book chapters, and he holds 10 patents related to immunotherapy. He is the recipient of numerous honors and awards and has served
on many editorial boards.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals